第二代抗精神病药物与安慰剂相比的神经认知益处：基于系统评价的证据不足 - Suppr

Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review.

作者信息

Takeuchi Hiroyoshi, Thiyanavadivel Sadhana, Fervaha Gagan, Remington Gary

机构信息

Schizophrenia Division, Complex Care & Recovery Program, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, Canada and Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan

出版信息

J Clin Psychopharmacol. 2017 Apr;37(2):274-276. doi: 10.1097/JCP.0000000000000662.

DOI:10.1097/JCP.0000000000000662

PMID:28129314

Abstract

摘要

相似文献

Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review.

J Clin Psychopharmacol. 2017 Apr;37(2):274-276. doi: 10.1097/JCP.0000000000000662.

A Case Study of Clozapine and Cognition: Friend or Foe?

J Clin Psychopharmacol. 2018 Apr;38(2):152-153. doi: 10.1097/JCP.0000000000000847.

Safety and Efficacy in Randomized Controlled Trials of Second-Generation Antipsychotics Versus Placebo for Cognitive Impairments in Schizophrenia: A Meta-Analysis.

J Clin Psychopharmacol. 2022;42(2):227-229. doi: 10.1097/JCP.0000000000001232.

5-HT1A C-1019G (rs6295) Predicts Aripiprazole Treatment Response Specifically for Cognitive and Depressive Symptoms in Schizophrenia.

J Clin Psychopharmacol. 2017 Feb;37(1):114-118. doi: 10.1097/JCP.0000000000000628.

Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition.

Transl Psychiatry. 2018 Mar 6;8(1):58. doi: 10.1038/s41398-018-0104-z.

Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics.

Pharmacogenomics. 2018 Aug 1;19(12):927-930. doi: 10.2217/pgs-2018-0083. Epub 2018 Jul 20.

Improving Current Treatments for Schizophrenia.

Drug Dev Res. 2016 Nov;77(7):357-367. doi: 10.1002/ddr.21337. Epub 2016 Sep 16.

Pharmacological interventions in social cognition deficits: A systematic mapping review.

Psychiatry Res. 2018 Dec;270:57-67. doi: 10.1016/j.psychres.2018.09.012. Epub 2018 Sep 11.

A pilot open study of long term high dose creatine augmentation in patients with treatment resistant negative symptoms schizophrenia.

Isr J Psychiatry Relat Sci. 2015;52(1):6-10.

Involvement of vascular endothelial growth factor in schizophrenia.

Neurosci Lett. 2021 Aug 24;760:136093. doi: 10.1016/j.neulet.2021.136093. Epub 2021 Jun 30.

引用本文的文献

Efficacy of Cortical-Hippocampal Target Intermittent Theta Burst Stimulation (iTBS) on Associative Memory of Schizophrenia: A Double-Blind, Randomized Sham-Controlled Trial.

Neuropsychiatr Dis Treat. 2024 Oct 10;20:1941-1955. doi: 10.2147/NDT.S468219. eCollection 2024.

Low-dose lithium adjunct to atypical antipsychotic treatment nearly improved cognitive impairment, deteriorated the gray-matter volume, and decreased the interleukin-6 level in drug-naive patients with first schizophrenia symptoms: a follow-up pilot study.

Schizophrenia (Heidelb). 2023 Oct 14;9(1):71. doi: 10.1038/s41537-023-00400-w.

Community participation factors and poor neurocognitive functioning among persons with schizophrenia.

Am J Orthopsychiatry. 2020;90(1):90-97. doi: 10.1037/ort0000399. Epub 2019 Jan 24.

Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.

Psychopharmacology (Berl). 2019 Feb;236(2):545-559. doi: 10.1007/s00213-018-5133-z. Epub 2018 Nov 30.

Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes.

Front Psychiatry. 2018 Sep 20;9:447. doi: 10.3389/fpsyt.2018.00447. eCollection 2018.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review.

作者信息

Takeuchi Hiroyoshi, Thiyanavadivel Sadhana, Fervaha Gagan, Remington Gary

机构信息

出版信息

J Clin Psychopharmacol. 2017 Apr;37(2):274-276. doi: 10.1097/JCP.0000000000000662.

DOI:10.1097/JCP.0000000000000662

PMID:28129314

Abstract

摘要

相似文献

Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review.

J Clin Psychopharmacol. 2017 Apr;37(2):274-276. doi: 10.1097/JCP.0000000000000662.

A Case Study of Clozapine and Cognition: Friend or Foe?

J Clin Psychopharmacol. 2018 Apr;38(2):152-153. doi: 10.1097/JCP.0000000000000847.

Safety and Efficacy in Randomized Controlled Trials of Second-Generation Antipsychotics Versus Placebo for Cognitive Impairments in Schizophrenia: A Meta-Analysis.

J Clin Psychopharmacol. 2022;42(2):227-229. doi: 10.1097/JCP.0000000000001232.

5-HT1A C-1019G (rs6295) Predicts Aripiprazole Treatment Response Specifically for Cognitive and Depressive Symptoms in Schizophrenia.

J Clin Psychopharmacol. 2017 Feb;37(1):114-118. doi: 10.1097/JCP.0000000000000628.

Altered brainstem responses to modafinil in schizophrenia: implications for adjunctive treatment of cognition.

Transl Psychiatry. 2018 Mar 6;8(1):58. doi: 10.1038/s41398-018-0104-z.

Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics.

Pharmacogenomics. 2018 Aug 1;19(12):927-930. doi: 10.2217/pgs-2018-0083. Epub 2018 Jul 20.

Improving Current Treatments for Schizophrenia.

Drug Dev Res. 2016 Nov;77(7):357-367. doi: 10.1002/ddr.21337. Epub 2016 Sep 16.

Pharmacological interventions in social cognition deficits: A systematic mapping review.

Psychiatry Res. 2018 Dec;270:57-67. doi: 10.1016/j.psychres.2018.09.012. Epub 2018 Sep 11.

A pilot open study of long term high dose creatine augmentation in patients with treatment resistant negative symptoms schizophrenia.

Isr J Psychiatry Relat Sci. 2015;52(1):6-10.

Involvement of vascular endothelial growth factor in schizophrenia.

Neurosci Lett. 2021 Aug 24;760:136093. doi: 10.1016/j.neulet.2021.136093. Epub 2021 Jun 30.

引用本文的文献

Efficacy of Cortical-Hippocampal Target Intermittent Theta Burst Stimulation (iTBS) on Associative Memory of Schizophrenia: A Double-Blind, Randomized Sham-Controlled Trial.

Neuropsychiatr Dis Treat. 2024 Oct 10;20:1941-1955. doi: 10.2147/NDT.S468219. eCollection 2024.

Schizophrenia (Heidelb). 2023 Oct 14;9(1):71. doi: 10.1038/s41537-023-00400-w.

Community participation factors and poor neurocognitive functioning among persons with schizophrenia.

Am J Orthopsychiatry. 2020;90(1):90-97. doi: 10.1037/ort0000399. Epub 2019 Jan 24.

Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.

Psychopharmacology (Berl). 2019 Feb;236(2):545-559. doi: 10.1007/s00213-018-5133-z. Epub 2018 Nov 30.

Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes.

Front Psychiatry. 2018 Sep 20;9:447. doi: 10.3389/fpsyt.2018.00447. eCollection 2018.

Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Neurocognitive Benefits of Second-Generation Antipsychotics Versus Placebo: Insufficient Evidence Based on a Systematic Review.

作者信息

机构信息

出版信息

相似文献

引用本文的文献